The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
Open accessAbstract
BACKGROUND: Bempedoic acid, an ATP citrate lyase inhibitor, reduces low-density lipoprotein (LDL) cholesterol levels and is associated with a low incidence of muscle-related adverse events; its effects on cardiovascular outcomes remain uncertain. METHODS: We conducted a double-blind, randomized, placebo-controlled trial involving patients who were unable or unwilling to take statins owing to unacceptable adverse effects ("statin-intolerant" patients) and had, or were at high risk for, cardiovascular disease. The patients were assigned to receive oral bempedoic acid, 180 mg daily, or placebo. The primary end point was a four-component composite of major adverse cardiovascular events, defined as death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization. RESULTS: A total of 13,970 patients underwent randomization; 6992 were assigned to the bempedoic acid group and 6978 to the placebo group. The median duration of follow-up was 40.6 months. The mean LDL cholesterol level at baseline was 139.0 mg per deciliter in both groups, and after 6 months, the reduction in the level was greater with bempedoic acid than with placebo by 29.2 mg per deciliter; the observed difference in the percent reductions was 21.1 percentage points in favor of bempedoic acid. The incidence of a primary end-point event was significantly lower with bempedoic acid than with placebo (819 patients [11.7%] vs. 927 [13.3%]; hazard ratio, 0.87; 95% confidence interval [CI], 0.79 to 0.96; P = 0.004), as were the incidences of a composite of death from cardiovascular causes, nonfatal stroke, or nonfatal myocardial infarction (575 [8.2%] vs. 663 [9.5%]; hazard ratio, 0.85; 95% CI, 0.76 to 0.96; P = 0.006); fatal or nonfatal myocardial infarction (261 [3.7%] vs. 334 [4.8%]; hazard ratio, 0.77; 95% CI, 0.66 to 0.91; P = 0.002); and coronary revascularization (435 [6.2%] vs. 529 [7.6%]; hazard ratio, 0.81; 95% CI, 0.72 to 0.92; P = 0.001). Bempedoic acid had no significant effects on fatal or nonfatal stroke, death from cardiovascular causes, and death from any cause. The incidences of gout and cholelithiasis were higher with bempedoic acid than with placebo (3.1% vs. 2.1% and 2.2% vs. 1.2%, respectively), as were the incidences of small increases in serum creatinine, uric acid, and hepatic-enzyme levels. CONCLUSIONS: Among statin-intolerant patients, treatment with bempedoic acid was associated with a lower risk of major adverse cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization). (Funded by Esperion Therapeutics; CLEAR Outcomes ClinicalTrials.gov number, NCT02993406.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The CLEAR Outcomes trial randomized 13,970 patients with established or high risk for CVD, intolerance to statins, and LDL-C level ≥ 100 mg/dL to receive bempedoic acid (180 mg daily) or placebo [131]. Bempedoic acid reduced the risk of MACE by − 13% (HR 0.87, 95% CI 0.79–0.96, p = 0.004) and resulted in a − 21.1% greater reduction in LDL-C levels”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [133]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is important to note that ∼19% of individuals were on very-low-dose statin therapy at baseline (135).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [135]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This substantially exceeded other oral non-statin therapies, as ezetimibe lowers LDL-C by 18–25%, bempedoic acid by 17–21%, and their combination by ∼36–40% [[21], [22], [23], [24]]”
From Oral PCSK9 inhibitors for elevated LDL-C: A systematic review and meta-analysis of randomized trials (2026) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the CLEAR-Outcomes trial, an intriguing observation was that BA’s relative risk reduction for the primary composite outcome differed significantly between the primary and secondary prevention groups (with hazard ratios of 0.68 versus 0.91 respectively) [7].”
From The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A higher frequency of gout (3.1% versus 2.1%) and cholelithiasis (2.2% versus 1.2%) was observed with bempedoic acid than with placebo [133].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [133]
The cited source says what the claim attributes to it.
In the citing paper
“The Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid or Placebo (CLEAR Outcomes) trial found a reduction in four-point major adverse cardiovascular events by 13% compared with placebo for individuals with established ASCVD (70% of population) or at high risk for ASCVD (30% of population) a”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [141]
The cited source says what the claim attributes to it.
In the citing paper
“Clinical trials have shown bempedoic acid reduces LDL-C levels and the CLEAR Outcomes trial demonstrated a significant reduction in MACE compared with placebo in patients who are statin intolerant [[12], [13], [14], [15],17].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“The CLEAR Outcomes (Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen) trial reported cardiovascular outcomes in a mixed population of primary and secondary prevention patients unable or unwilling to take guideline-recommended doses of statins.11”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“This primary prevention cohort was a prespecified subgroup that represented 30% of the total enrolled within a larger trial that included a mixed population of primary and secondary prevention patients.11”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“This was followed by recent data from the CLEAR Outcomes trial showing reductions in clinical events [7].”
From The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“These differences are likely attributable to a lack of statistical power and imprecise estimates as the largest outcomes-based trial, CLEAR Outcomes, had not yet been published at the time of the previous meta-analyses but is included in our meta-analysis [7].”
From The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, most of the trials included in this analysis had relatively short follow-up durations with the exception of CLEAR Outcomes [7] and CLEAR Harmony [12].”
From The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials (2024) · cites this paper as [7]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The overall risk of bias was low 7 of 11 trials [7, 9–12, 15, 16], with 4 trials being assessed as having a moderate risk of bias [8, 13, 14, 17].”
From The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredIn the citing paper
“Among the 6992 patients assigned to the active arm of the study 45% had T2DM.Bempedoic acid was associated with a significantly lower incidence of the four-component composite primary endpoint of CV death, non-fatal MI, non-fatal stroke, or coronary revascularization and a higher incidence of some adverse events (gout and cholelithiasis) at the 40.6 month follow-up.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [282]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Self-citationStatins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Self-citationStroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
Self-citationSafety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., Robinson, P. L., & Ballantyne, C. M. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1803917 · Cited by 807
Self-citationPinkosky, S. L., Newton, R. S., Day, E. A., Ford, R. J., Lhotak, S., Austin, R. C., Birch, C. M., Smith, B. K., Filippov, S., Groot, P. H. E., et al. (2016) · Nature Communications · doi:10.1038/ncomms13457 · Cited by 498
Goldberg, A. C., Leiter, L. A., Stroes, E. S. G., Baum, S. J., Hanselman, J. C., Bloedon, L. T., Lalwani, N. D., Patel, P. M., Zhao, X., & Duell, P. B. (2019) · JAMA · doi:10.1001/jama.2019.16585 · Cited by 481
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,000
Manoj, S., Shah, J., Kumar, D., Pradhan, A. K., Kinare, A. B., Sharma, A. K., Aditya, M. S., Raj, R. A., Raina, A. A., Patel, A., et al. (2023) · Cardiology and Angiology An International Journal · doi:10.9734/ca/2023/v12i4350 · Cited by 2
Schlagen Frauenherzen anders? – Geschlechterunterschiede im Lipidmanagement
Muck, M. A., & Baessler, A. (2025) · Journal für Endokrinologie Diabetologie und Stoffwechsel · doi:10.1007/s41969-025-00263-9 · Cited by 2
In vivo effects of bempedoic acid on microdosed CYP probe drugs
Stoll, F., Amato, S., Burhenne, J., & Blank, A. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1544956 · Cited by 2
Ferrara, F., Zovi, A., Langella, R., Panico, A., Scognamiglio, M., Trama, U., Nava, E., Capuozzo, M., Primiano, F., & Russo, G. (2025) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2025.2493728 · Cited by 2
Update on statin-associated myopathy symptoms in the view of new clinical management strategies
Musumeci, O., & Drago, S. F. A. (2025) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001405 · Cited by 2
Addressing Disparities in the Screening and Treatment of Dyslipidemia – A Call to Action
Converse, E., Watson, K., Ahmad, Z., Yang, E., Gianos, E., Sagheer, U., Virani, S. S., & Kalra, D. K. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00769-6 · Cited by 2
Bempedoic Acid and the Uric Acid Paradox: Reflections on the Recent Meta-analysis
Bonanni, L., & Ferri, N. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07781-3 · Cited by 2
Lipid metabolism disorders in metabolic syndrome
Polyakova, E. A. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6539 · Cited by 2
Inhibition of ATP citrate lyase does not affect muscle mitochondrial activity in apoE-/- mice
Macchi, C., Fichtner, I., Mohamed, T., Franchi, E., Rizzuto, A. S., Pavanello, C., Gindlhuber, J., Nerini, S., Sirtori, C. R., Osto, E., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118726 · Cited by 2
Inflammation and atherosclerotic cardiovascular disease: where do we go from here?
Waksman, O., & Waksman, R. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001009 · Cited by 2
Cardiovascular Therapeutics at the Crossroads: Pharmacological, Genetic, and Digital Frontiers
Vetrano, E., Caturano, A., Nilo, D., Lorenzo, G. D., Tagliaferri, G., Piacevole, A., Donnarumma, M., Iadicicco, I., Picco, S., Moretto, S. M., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18111703 · Cited by 2
Masuda, D., Kajinami, K., Sakayoshi, N., Yokota, D., Nagamine, M., Isogai, Y., & Yamashita, S. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65947 · Cited by 2
Wang, Y., Zhang, B., & Xie, X. (2025) · Stroke and Vascular Neurology · doi:10.1136/svn-2025-004693 · Cited by 2
Xiao, Q., Wang, M., Wang, S., Wang, L., & Ding, H. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-025-07647-0 · Cited by 2
Garagoli, F., Masson, W. M., & Barbagelata, L. (2026) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-025-01476-w · Cited by 2
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2026) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2026.01.001 · Cited by 2
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101725 · Cited by 2
Metabolic control of innate immune activation in TET2-mutant clonal hematopoiesis
Kim, P. G., Hergott, C. A., Miller, A. P., Deik, A., Boileau, M., Bullock, K. H., Pierce, K. A., Choy, A. H., Shin, W., McConkey, M. E., et al. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.01.006 · Cited by 3
Katzmann, J. L., & Laufs, U. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01390-7 · Cited by 2
Oterino, A., Olmo, R. F., Toro, M. M., & Cordero, A. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120714 · Cited by 2
Obicetrapib safety analysis: Pooled phase 3 clinical trial experience
Nelson, A. J., Kastelein, J. J. P., Ditmarsch, M., Hall, C., Kling, D., Ortiz, N., Wicks, D. L., Hsieh, A., Szarek, M. J., Ray, K. K., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101547 · Cited by 2
Self-citationHyperuricemia risk in bempedoic acid-treated hyperlipidemic patients
Su, P., Tsai, D. H., Hsieh, M. H., Vairaperumal, T., Lai, E. C.-C., & Liu, P. Y. (2026) · Communications Medicine · doi:10.1038/s43856-026-01545-2 · Cited by 2
Reconsider the future of interventional cardiology: restoration, reappraisal, and revolution
Ge, J. (2026) · Cardiology Plus · doi:10.1097/cp9.0000000000000155 · Cited by 2
Li, D., Wu, L., & Li, Y. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189588 · Cited by 2
Are we underestimating the benefits of lipid-lowering therapies?
Pirillo, A., Casula, M., Olmastroni, E., Scotti, S., Corsini, A., & Catapano, A. L. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100140 · Cited by 2
Dyslipidaemias in cancer patients
Nazir, M. S., Cegla, J., Andrés, M. S., Ray, K. K., & Lyon, A. R. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag265 · Cited by 2
Self-citationChai, X.-J., Wei, G., Chen, W., Min, D.-Y., Wang, Y., & Guan, L. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1801502 · Cited by 2
Development and Validation of a Simplified Martin-Hopkins LDL-C Equation Using Machine Learning
Park, J., Fan, L., Marzinke, M. A., Sokoll, L. J., Muthukumar, A., Murphy, S. A., Sabatine, M. S., Gurudu, R., Meeusen, J. W., & Martin, S. S. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2026.2314 · Cited by 2
Cardiovascular Outcomes in Response to Achieved LDL-C Levels After PCI in ACS and CCS
Kataoka, Y., Nicholls, S. J., Ray, K. K., Katasako-Yabumoto, A., Kitahara, S., Hosoda, H., Mitsui, K., Murai, K., Sawada, K., Iwai, T., et al. (2026) · JACC Asia · doi:10.1016/j.jacasi.2026.07.004 · Cited by 2
Self-citationGiugliano, R. P., Bohula, E. A., Bellavia, A., Ferrari, G. M. D., Leiter, L. A., Nicolau, J. C., Bhatia, A. K., Murphy, S. A., Liu, L., Wang, H., et al. (2026) · Circulation · doi:10.1161/circulationaha.126.082436 · Cited by 2
ASN Kidney Health Guidance on the Cardiovascular-Kidney-Metabolic Syndrome
Bansal, N., Bjornstad, P., Bress, A. P., Chang, T. I., Cheng, X. S., Estrella, M. M., Go, A. S., Mottl, A. K., Navaneethan, S. D., Neuen, B. L., et al. (2026) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000001231 · Cited by 3
Zheng, J., Hou, Z., Yuan, J., Zhao, X., Wang, Y., Li, J., Zhang, W., Dou, K., & Lü, B. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-070832 · Cited by 2
Bempedoic acid and cardiovascular outcomes
BMJ Publishing Group Ltd (2023) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2023.000054 · Cited by 2
The year in cardiovascular medicine 2023: the top 10 papers in dyslipidaemias
Tokgözoğlu, L. S., Orringer, C. E., & Catapano, A. L. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad837 · Cited by 2
Research Progress on Hyperlipidemia
李, 成. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.141235 · Cited by 2
Nisar, S., Sohail, S., Fatima, S., Akhtar, M. T., Ahmad, M., Hanif, M. W., Khan, M., Mehmoodi, A., & Malik, J. (2024) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.55729/2000-9666.1313 · Cited by 2
Cardiology: What You May Have Missed in 2023
Alfraih, A., Tago, A., LaCombe, M. A., & Kussmaul, W. G. (2024) · Annals of Internal Medicine · doi:10.7326/m24-0581 · Cited by 2
Natale, F., Franzese, R., Marotta, L., Mollo, N., Solimene, A., Luisi, E., Gentile, C., Loffredo, F. S., Golino, P., & Cimmino, G. (2024) · Life · doi:10.3390/life14060679 · Cited by 2
Serour, M. H., Egaimi, M., & Khan, Z. U. (2024) · Cureus · doi:10.7759/cureus.61572 · Cited by 2
Navigating the Maze of Kinases: CaMK-like Family Protein Kinases and Their Role in Atherosclerosis
Teuwen, J. T. J., van der Vorst, E. P. C., & Maas, S. L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116213 · Cited by 2
Yasmin, F., Najeeb, H., Moeed, A., Ali, E., Umar, M., Ullah, I., Shah, N. P., & Alraies, M. C. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001715 · Cited by 2
Elnaggar, M., Miller, A. M., Sil, A., & Viljoen, A. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2400273 · Cited by 2
Stach, K., Richter, H., Fraass, U., & Stein, A. (2024) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/17539447241277402 · Cited by 2
Bruun, K., & Mortensen, M. B. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001188 · Cited by 2
Sex differences in LDL ‐C reduction response to evolocumab: A propensity score matching analysis
He, Y., Wei, Y., Guang-ming, H., Liu, G., Lin, Z., Liu, T., Jiang, X., & Lu, J. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.4619 · Cited by 2
Yoshimitsu, Y., Awaya, T., Kawagoe, N., Kunimasa, T., Iijima, R., & Hara, H. (2024) · Diseases · doi:10.3390/diseases12110297 · Cited by 2
Managing Myotonic Dystrophy Type 1 Complicated by Metabolic Syndrome
Pagnoni, G., Nassar, A., Grossule, F., Paolini, M., Maini, A., Mattioli, A. V., Boriani, G., & Coppi, F. (2024) · JACC Case Reports · doi:10.1016/j.jaccas.2024.102761 · Cited by 2
El control estricto del colesterol aterogénico en la prevención de las enfermedades cardiovasculares
Guijarro, C. (2024) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2024.10.004 · Cited by 2
Manosroi, W., Phinyo, P., Phimphilai, M., Hutayanon, P., Gunaparn, S., Phrommintikul, A., & Wongcharoen, W. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.01.002 · Cited by 2
Liu, M., Yin, N., Zhu, Y., Du, A., Cai, C.-Y., & Leng, P. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1398023 · Cited by 2
Muiesan, M. L., Virdis, A., Tocci, G., Borghi, C., Cicero, A. F. G., Ferri, C., Pirro, M., Corsini, A., & Volpe, M. (2025) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-024-00700-x · Cited by 2
Interplay of Metastasis, Cancer Stem Cells, and Energy Metabolism in Cancer Progression
Mal, A. (2025) · Current Tissue Microenvironment Reports · doi:10.1007/s43152-025-00059-8 · Cited by 2
Satyanarayanan, Y. V., Rayaprolu, V. L. G., Durugu, S. R., Katukuri, N., & Nemani, L. (2025) · Indian Journal of Cardiovascular Disease in Women · doi:10.25259/ijcdw_59_2025 · Cited by 2
Hypercholesterinämie und kardiovaskuläres Risiko
Sinning, D., & Landmesser, U. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1932-6448 · Cited by 2
Dyslipidemia in Metabolic Syndrome
Toh, S.-A. E. S., & Lee, M. H. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_58-1 · Cited by 2
Goyal, A., Shah, S., Dahal, K., Changez, M. I. K., Tariq, M. D., Zuhair, V., Shamim, U., Abbasi, H. Q., Shrestha, A. B., Sah, R., et al. (2024) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000302 · Cited by 2
Effects of ACLY Inhibition on Body Weight Distribution: A Drug Target Mendelian Randomization Study
Gill, D., Dib, M., Gill, R., Bornstein, S. R., Burgess, S., & Birkenfeld, A. L. (2024) · Genes · doi:10.3390/genes15081059 · Cited by 2
Management of Dyslipidemia in Chronic Kidney Disease
Vedamurthy, D., Sagheer, U., Patel, A., Singh, G., & Kalra, D. K. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00763-y · Cited by 2
Cinza‐Sanjurjo, S., Pallarés‐Carratalá, V., Rodríguez, Á. D., Fierro-González, D., Turégano-Yedro, M., & García, J. P. (2025) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2025.102460 · Cited by 2
Bruceine E attenuates hepatic steatosis through modulation of PI3K/AKT/NFκB signalling pathway
Man, F., Jayanti, N. E., Leow, C. Y., & Choo, C. (2025) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgaf016 · Cited by 2
Ferrara, F., Zovi, A., Langella, R., Panico, A., Scognamiglio, M., Trama, U., Nava, E., Capuozzo, M., Primiano, F., & Russo, G. (2025) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2025.05.002 · Cited by 2
Recent progress in anti-atherosclerosis strategies and prospective therapeutic targets
Wang, Z., He, X., Bai, H., Feng, D., Qu, Y., Zhang, Y., Lee, R. J., & Sun, Y. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126122 · Cited by 4
Inflammation and cardiometabolic disease in South Asians: The fire and fire tenders
Balaji, K., Chahil, V., Shakoor, A., Kalra, D., & Vijayaraghavan, K. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.10.068 · Cited by 2
Bempedoic acid: a CLEAR therapeutic option for statin-intolerant patients?
Volpe, M., & Patrono, C. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad206 · Cited by 2
Korosoglou, G., Giesen, A., Geiss, E., & Stach, K. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1203832 · Cited by 2
Vila, À., Pons, E., García, P. T., Vidal, D., López, S., & Grau, A. (2023) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2023.06.003 · Cited by 2
Pharmacotherapy of Obesity and Metabolic Syndrome
Duan, D., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_44 · Cited by 2
Bempedoic Acid, an Inhibitor of Cholesterol Biosynthesis, Reduces Cardiovascular Events
Jialal, I., & Olatunbosun, S. T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103463 · Cited by 2
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk
Zhang, D., Wu, H., & Gong, S. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2510693 · Cited by 2
Systematic literature review on the real-world effectiveness and safety of bempedoic acid
Cicero, A. F. G., Cannon, C. P., Gautam, R., Anwar, S., Ghatak, A., Sarnes, E., Powell, H. A., Chhabra, R., & Jawla, S. (2026) · Atherosclerosis Plus · doi:10.1016/j.athplu.2026.100562 · Cited by 1
“Clinical trials have shown bempedoic acid reduces LDL-C levels and the CLEAR Outcomes trial demonstrated a significant reduction in MACE compared with placebo in patients who are statin intolerant [12 – 15 , 17 ].”
Novel LDL-cholesterol lowering therapies: A step forward a personalized medicine
Averna, M. R., & Cefalu, A. B. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.04.026 · Cited by 1
Serhiyenko, V. A., & Serhiyenko, A. A. (2023) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.19.3.2023.1275 · Cited by 1
Dey, H., Agarwal, V., Ali, M. N., Upadhyay, A., Shafieq, S., Dixit, B., Tomar, S., & Tarannum, M. (2024) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v14i4.6533 · Cited by 1
Bempedoic acid: A new player in lipid-lowering
Riesen Walter, F. (2024) · Journal of Cardiovascular Medicine and Cardiology · doi:10.17352/2455-2976.000205 · Cited by 1
Efficacy and Safety of Bempedoic Acid as a Treatment Option for Hyperlipidemia: A Systematic Review
Sharif, M. H., Orakzai, A. A., Khaleeque, M., Raza, S. S., Khan, O. S., Jan, M. H., Ahmed, A., & Arsalan, M. (2024) · Advances in Clinical Medical Research and Healthcare Delivery · doi:10.53785/2769-2779.1198 · Cited by 1
Efficacy and Safety of Bempedoic Acid in Lipid Disorder Therapy: A Review of Clinical Trials
Dąbrowska, P., Żuber, M., & Dacka, M. (2024) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.208 · Cited by 1
Kommentar zu den Leitlinien (2023) der ESC zum Akuten Koronarsyndrom (ACS)
Waßmann, S., Giménez, M. R., Cassese, S., Ghanem, A., Schüpke, S., Ong, P., Schirmer, S. H., Thiele, H., & Mehilli, J. (2024) · Die Kardiologie · doi:10.1007/s12181-024-00705-9 · Cited by 1
Management of cardiometabolic diseases: A clinician's perspective
Bassi, N. S., Mohan, P., & Itchhaporia, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95469-3.00002-4 · Cited by 1
Mayer, F., Innerhofer, R., Köller, T., & Binder, C. J. (2024) · Learning materials in biosciences · doi:10.1007/978-3-031-64591-4_10 · Cited by 1
Baptista, E. C. M. S., Pereira, C. S. G. P., García, P. A., Ferreira, I. C. F. R., & Barreira, J. C. M. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.01.026 · Cited by 1
Cardozo, F. A. M., Bichuette, L. D., & Caramelli, B. (2025) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2025.2463348 · Cited by 1
Ferrara, F., Zovi, A., Langella, R., Panico, A., Scognamiglio, M., Trama, U., Nava, E., Capuozzo, M., Primiano, F., & Russo, G. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-03862-0 · Cited by 1
Zhang, W.-J., Wang, J., Ouyang, Z., Luo, S.-R., Chen, Z.-K., He, Y.-K., Luo, M.-J., & Liao, X.-X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1584273 · Cited by 1
Ali, A., Bhimani, S., Karmani, V. K., Dhillon, R. A., Saeed, S., Amir, A., Patel, P. S., Asif, A., Baig, U. A., Shamoon, S., et al. (2025) · Qatar medical journal · doi:10.5339/qmj.2025.51 · Cited by 1
Obicetrapib and CETP inhibition: An exception to the rule?
Cariou, B., & Moulin, P. (2025) · Med · doi:10.1016/j.medj.2025.100780 · Cited by 1
Cao, Y., Meng, X., Xu, X., Xia, C., Yang, C., Cui, X., He, Q., & Song, G. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01828 · Cited by 1
Schiele, F., Farnier, M., & Borsik, B. (2025) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2025.08.008 · Cited by 1
Myerson, M. L., Warden, B. A., Saseen, J. J., & Paparodis, R. D. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.044134 · Cited by 1
Warden, B. A., & Duell, P. B. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.10.065 · Cited by 1
Antibody-Based Therapeutics for Hypercholesterolemia
Tomlinson, B., & Chan, P. (2025) · Biologics · doi:10.2147/btt.s500456 · Cited by 1
Cardiovascular Pharmacotherapy and Glucose Metabolism: The Good, the Bad and the Unsightly
Bianchettin, R. G., Poirier, P., López-Jiménez, F. A., Lavie, C. J., & Piché, M. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00777-2 · Cited by 1
Abdullah, M., Khalid, N., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001111 · Cited by 1
ESC-Leitlinien-Update 2025 zur Dyslipidämie
Hohneck, A. L., & Weingärtner, O. (2025) · Herz · doi:10.1007/s00059-025-05354-6 · Cited by 1
A Year in Coronary Artery Disease: A Focussed 2024 Update
Swinn, T., O’Shea, D., & Dastidar, A. (2025) · British Journal of Hospital Medicine · doi:10.12968/hmed.2025.0297 · Cited by 1
Razavi, A. C., Sokolsky, M., Belanger, M., Blazoski, C. M., Spitz, J. A., Sperling, L. S., Blumenthal, R. S., & Whelton, S. P. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101417 · Cited by 1
Management of metabolic dysfunction and cardiovascular risk in patients with MASLD
Danpanichkul, P., Blaney, H. L., Perelli, J., Huerta, P., Idalsoaga, F. J., Arrese, M. A., Arab, J. P., Loomba, R. S., & Díaz, L. A. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.32 · Cited by 1
Dyslipidemias in Chronic Kidney Disease: Pathophysiology and Emerging Therapies
Capón, I. M., Lerma, E. V., Anandh, U., So, P. N., & Hassanein, M. (2026) · Indian Journal of Nephrology · doi:10.25259/ijn_711_2025 · Cited by 1
LDL-C lowering in patients treated with bempedoic acid in a real-world cohort
Nelson, J., Bloedon, L. T., Lewandowski, D., Vaduganathan, M., Ajose, M., Bonafede, M., & Sarnes, E. (2026) · Atherosclerosis Plus · doi:10.1016/j.athplu.2026.01.007 · Cited by 1
Self-citationThe 2025 ESC/EAS Dyslipidaemia Focused Update: Clinical Interpretation and Practical Implications
Bonanni, L., Cutolo, A., & Ferri, N. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07855-w · Cited by 1
Deciphering the role of mitochondrial cytochrome C oxidase subunit 4 in cardiac health and disease
Indian, P. A., Trivedi, M. V., & Gaikwad, A. B. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124295 · Cited by 1
Metadata
- Authors
- Nissen, S. E., Lincoff, A. M., Brennan, D., Ray, K. K., Mason, D., Kastelein, J. J. P., Thompson, P. D., Libby, P., Cho, L., Plutzky, J., Bays, H. E., Moriarty, P. M., Menon, V., Grobbee, D. E., Louie, M. J., Chen, C.-F., Li, N., Bloedon, L., Robinson, P., Horner, M., Sasiela, W. J., McCluskey, J., Davey, D., Fajardo-Campos, P., Petrovic, P., Fedacko, J., Zmuda, W., Lukyanov, Y., & Nicholls, S. J.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cleveland Clinic, Cleveland (S.E.N., A.M.L., D.B., D.M., L.C., V.M., J.M., D.D.); Imperial College London, London (K.K.R.); University of Amsterdam Academic Medical Center, Amsterdam (J.J.P.K.), and University Medical Center Utrecht, Utrecht (D.E.G.) — both in the Netherlands; Hartford Hospital, Hartford, CT (P.D.T.); Brigham and Women’s Hospital, Harvard Medical School, Boston (P.L., J.P.); Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY (H.E.B.); University of Kansas Medical Center, Kansas City (P.M.M.); Esperion Therapeutics, Ann Arbor, MI (M.J.L., C.-F.C., N.L., L.B., P.R., M.H., W.J.S.); Centro de Investigación Cardiovascular y Metabólica, Tijuana, Mexico (P.F.-C.); General Hospital Sveti Luka, Smederevo, Serbia (P.P.); Center of Clinical and Preclinical Research Medipark, Pavol Jozef Šafárik University, Košice, Slovakia (J.F.); Medicome, Oświęcim, Poland (W.Z.); Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia (Y.L.); and Victorian Heart I...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-04-13
- Volume
- 388
- Issue
- 15
- Pages
- 1353-1364
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4323075797
- Semantic Scholar
- 33b876475ba15ddd5ffc66ad5046afe4cb9173b0
- Cited by
- 988
- References
- 21
- Citations by year
- 2026: 266 · 2025: 261 · 2024: 270 · 2023: 189
- FWCI
- 263.23
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Esperion Therapeutics
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- bempedoic acid, statin intolerance, ATP-citrate lyase inhibitor, LDL cholesterol lowering, major adverse cardiovascular events, cardiovascular disease prevention, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, stroke, coronary revascularization, hypercholesterolemia, lipid-lowering therapy, statin adverse effects
- MeSH terms
- Administration, Oral, Hypolipidemic Agents, Cardiovascular Diseases, Dicarboxylic Acids, Double-Blind Method, Fatty Acids, Humans, Myocardial Infarction, Myocardial Revascularization, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
